Australia markets open in 48 minutes

Ionis Pharmaceuticals, Inc. (0JDI.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
41.77-0.48 (-1.14%)
At close: 07:00PM BST
Full screen
Previous close42.25
Bid0.00 x N/A
Ask0.00 x N/A
Day's range41.71 - 41.88
52-week range33.21 - 53.94
Avg. volume351
Market cap57.857M
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)-0.03
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

    Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced full results from the Phase 3 Balance study of Ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The olezarsen 80 mg monthly dose met the primary endpoint of significantly reducing triglycerides (TGs) in patients with genetically validated FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprote

  • PR Newswire

    Ionis to present at upcoming investor conferences

    Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • PR Newswire

    Ionis to hold olezarsen Phase 3 data webcast

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.